JP2015519367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519367A5 JP2015519367A5 JP2015515159A JP2015515159A JP2015519367A5 JP 2015519367 A5 JP2015519367 A5 JP 2015519367A5 JP 2015515159 A JP2015515159 A JP 2015515159A JP 2015515159 A JP2015515159 A JP 2015515159A JP 2015519367 A5 JP2015519367 A5 JP 2015519367A5
- Authority
- JP
- Japan
- Prior art keywords
- sbv
- sequence
- seq
- cells
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000660220 Schmallenberg virus Species 0.000 claims 47
- 210000004027 cell Anatomy 0.000 claims 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 24
- 150000007523 nucleic acids Chemical group 0.000 claims 24
- 230000002163 immunogen Effects 0.000 claims 16
- 230000000295 complement effect Effects 0.000 claims 12
- 238000012258 culturing Methods 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 241000238631 Hexapoda Species 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 206010058874 Viraemia Diseases 0.000 claims 3
- 230000036244 malformation Effects 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 244000144980 herd Species 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170631 | 2012-06-01 | ||
| EP12170631.1 | 2012-06-01 | ||
| EP13157875 | 2013-03-05 | ||
| EP13157875.9 | 2013-03-05 | ||
| PCT/US2013/043146 WO2013181270A1 (en) | 2012-06-01 | 2013-05-29 | Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519367A JP2015519367A (ja) | 2015-07-09 |
| JP2015519367A5 true JP2015519367A5 (enExample) | 2016-07-14 |
| JP6250649B2 JP6250649B2 (ja) | 2017-12-20 |
Family
ID=48607368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515159A Expired - Fee Related JP6250649B2 (ja) | 2012-06-01 | 2013-05-29 | シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9370562B2 (enExample) |
| EP (1) | EP2855513B1 (enExample) |
| JP (1) | JP6250649B2 (enExample) |
| CN (1) | CN104350066B (enExample) |
| AR (1) | AR091240A1 (enExample) |
| AU (1) | AU2013267453C1 (enExample) |
| BR (1) | BR112014029515A2 (enExample) |
| CA (1) | CA2872961A1 (enExample) |
| DK (1) | DK2855513T3 (enExample) |
| EA (1) | EA034543B1 (enExample) |
| ES (1) | ES2617351T3 (enExample) |
| IN (1) | IN2014DN08927A (enExample) |
| MX (1) | MX363044B (enExample) |
| PL (1) | PL2855513T3 (enExample) |
| SG (1) | SG11201407619SA (enExample) |
| UY (1) | UY34840A (enExample) |
| WO (1) | WO2013181270A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6250649B2 (ja) | 2012-06-01 | 2017-12-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用 |
| EP2855512B1 (en) | 2012-06-01 | 2018-02-28 | Boehringer Ingelheim Vetmedica GmbH | Genomic sequences of schmallenberg virus and uses thereof |
| HK1216006A1 (zh) * | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法 |
| CN104232587B (zh) * | 2014-09-02 | 2016-08-17 | 中国检验检疫科学研究院 | 稳定表达施马伦贝格病毒核衣壳蛋白的细胞系及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0811736B2 (ja) * | 1986-08-07 | 1996-02-07 | 財団法人化学及血清療法研究所 | 牛流行熱・イバラキ病・アカバネ病３種混合不活化ワクチン |
| GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
| US6114108A (en) | 1995-08-29 | 2000-09-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of viral nucleic acids |
| US20080226682A1 (en) * | 2007-03-13 | 2008-09-18 | Peros Systems Technologies, Inc. | Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents |
| EP2062594A1 (en) | 2007-11-21 | 2009-05-27 | Wyeth Farma, S.A. | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| JP6250649B2 (ja) | 2012-06-01 | 2017-12-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用 |
| EP2855512B1 (en) | 2012-06-01 | 2018-02-28 | Boehringer Ingelheim Vetmedica GmbH | Genomic sequences of schmallenberg virus and uses thereof |
-
2013
- 2013-05-29 JP JP2015515159A patent/JP6250649B2/ja not_active Expired - Fee Related
- 2013-05-29 AU AU2013267453A patent/AU2013267453C1/en not_active Ceased
- 2013-05-29 SG SG11201407619SA patent/SG11201407619SA/en unknown
- 2013-05-29 IN IN8927DEN2014 patent/IN2014DN08927A/en unknown
- 2013-05-29 CA CA2872961A patent/CA2872961A1/en active Pending
- 2013-05-29 EA EA201401352A patent/EA034543B1/ru not_active IP Right Cessation
- 2013-05-29 ES ES13728288.5T patent/ES2617351T3/es active Active
- 2013-05-29 MX MX2014014521A patent/MX363044B/es unknown
- 2013-05-29 EP EP13728288.5A patent/EP2855513B1/en active Active
- 2013-05-29 CN CN201380028863.3A patent/CN104350066B/zh active Active
- 2013-05-29 WO PCT/US2013/043146 patent/WO2013181270A1/en not_active Ceased
- 2013-05-29 DK DK13728288.5T patent/DK2855513T3/en active
- 2013-05-29 US US13/904,752 patent/US9370562B2/en active Active
- 2013-05-29 PL PL13728288T patent/PL2855513T3/pl unknown
- 2013-05-29 BR BR112014029515A patent/BR112014029515A2/pt not_active IP Right Cessation
- 2013-05-31 AR ARP130101936 patent/AR091240A1/es not_active Application Discontinuation
- 2013-05-31 UY UY0001034840A patent/UY34840A/es unknown
-
2016
- 2016-05-19 US US15/158,790 patent/US9872897B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013782A (es) | Antigenos y vacunas dirigidos contra enterovirus humanos. | |
| RU2020117033A (ru) | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение | |
| JP2014532691A5 (enExample) | ||
| JP2011250797A5 (enExample) | ||
| Newcomer et al. | Approved and experimental countermeasures against pestiviral diseases: bovine viral diarrhea, classical swine fever and border disease | |
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| JP2015524422A5 (enExample) | ||
| EA201491889A1 (ru) | Соединения и способы для противовирусной терапии | |
| JP2015533841A5 (enExample) | ||
| MX373884B (es) | Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta. | |
| JP2015524421A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| JP2015519367A5 (enExample) | ||
| Loy et al. | Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle | |
| Wang et al. | Colloidal manganese salt improves the efficacy of rabies vaccines in mice, cats, and dogs | |
| JP2017526689A5 (enExample) | ||
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| CL2008003845A1 (es) | Vacuna que comprende una emulsion, una bacterina tratada termicamente a 55-70°c por 5-10 horas, que comprende una suspension de bacterias muertas de la especie leptospira bratislava, y de 1 a 13 virus causantes de enfermedad porcina. | |
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| WO2013104995A3 (en) | Compositions and methods for treating viral infections | |
| Kim et al. | Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection | |
| UA110505C2 (ru) | Імуногенні композиції bordetella bronchiseptica | |
| CN102847147B (zh) | 番鸭细小病毒病和番鸭呼肠孤病毒病二联活疫苗 | |
| AR081409A1 (es) | PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) | |
| EA201401352A1 (ru) | Вакцина против вируса шмалленберга (sbv), способы ее получения и применения |